Adagio Medical
ADGMAdagio Medical is a medical device company specializing in the development and commercialization of advanced catheter-based technologies for treating cardiac arrhythmias.
Earnings
Next report
Nov 11, 2026 (in 2 months)Competitors
By market cap
By revenue growth
Profile
Adagio Medical is a medical device company specializing in the development and commercialization of advanced catheter-based technologies for treating cardiac arrhythmias. Its core value proposition is the proprietary Ultra-Low Temperature Ablation (ULTA) platform, which uses near-critical nitrogen to create deep, durable lesions in heart tissue to treat complex conditions like ventricular tachycardia. The company's technology is designed to overcome the limitations of traditional radiofrequency ablation by providing better tissue penetration and procedural stability without the need for irrigation.
Adagio is an emerging innovator in the electrophysiology market, holding FDA Breakthrough Device Designation for its vCLAS system and targeting the underserved ventricular tachycardia market.
FAQ
- What is Adagio Medical's market cap?
- Adagio Medical (ADGM) has a market capitalization of $11.1M and trades on XNAS.
- Who are Adagio Medical's competitors?
- Adagio Medical's key competitors include Medtronic, Boston Scientific, Johnson & Johnson, and others. These companies compete in similar markets and product categories.
- Where is Adagio Medical headquartered?
- Adagio Medical is headquartered in United States of America. It has been publicly traded since 2024.